Floatz logo

Arimidex

Chronic Pain

DR. DIANE CHISESI NFS. MD. PHD.Active
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
73/ 100

Competitive context

79 Active assets in the Chronic Pain cohort.

Asset / SponsorPhaseRating
(±)-TRAMADOL
EMS
Phase 4BBB
LIDOCAINE
National and Kapodistrian University of Athens
Phase 4BBB
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE
Stanford University
Phase 4BBB
NEPENTHE
Bursa City Hospital
Phase 4BBB
FENTANYL
Aga Khan University
Phase 4BBB

View all 50 →

Same molecule, other indications

Arimidex is also rated in:

hormone receptor-positive breast cancerDormant
BBB
Indicative ·
74 / 100
View asset →
hypogonadotropic hypogonadismDormant
BBB
Indicative ·
73 / 100
View asset →
invasive breast carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →